The global nuclear medicine market is expected to grow significantly from USD 10.8 billion in 2023 to USD 32.9 billion by 2032, with a CAGR of 13.4%. This growth is mainly attributed to advancements in radiopharmaceuticals, a rising demand for early diagnosis, and innovations in hybrid imaging technologies. Key players in the market are engaging in strategic collaborations, like Bristol Myers Squibb's acquisition of RayzeBio, to enhance their product offerings. Overall, the future of the nuclear medicine market appears bright, with ample opportunities for growth driven by technological progress and increasing disease prevalence.
Wed, 27 Nov 2024 16:17:25 GMT | PharmiWeb.com